#1●Tigermed 2023 Interim Results Hangzhou Tigermed Consulting Co., Ltd. 300347.SZ/ 3347.HK August 2023 www.tigermedgrp.com 10/0#2Disclaimer This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2023 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk) for further information. All financials disclosed in this document are presented in accordance with International Financial Reporting Standards ("IFRS"s) except for those specifically noted otherwise. By reading these materials, you agree to be bound by the following limitations: The information herein has been prepared by representatives of Hangzhou Tigermed Consulting Co., Ltd., the "Company") solely for your information and have not been independently verified. The information herein does not constitute any recommendation regarding any securities of the Company or any of its subsidiaries. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The Company, nor any of their respective affiliates, controlling persons, directors, officers, employees, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of the information herein or its contents or otherwise arising in connection with the information herein. The information or opinions set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially without notice and shall only be considered current as of the date hereof. The information herein is based on the economic, regulatory, market and other conditions as in effect on the date hereof. Certain information in the materials contain information may be sourced from third parties, which has not been independently verified by the Company. It should be understood that any subsequent developments may affect the information contained herein, which the Company is not under an obligation to update, revise or affirm. You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company and any of its subsidiaries. Forward-Looking Statements The information communicated herein may contain certain "forward-looking statements", which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements. Non-IFRS Measure To supplement our financial information which are presented in accordance with IFRS, we use adjusted net profit attributable to owners of the Company as an additional financial measure, which is not required by, or presented in accordance with IFRS. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company before certain expenses and amortization. We define adjusted net profit attributable to owners of the Company as profit attributable to owners of the Company adjusted for (1) share-based compensation expense, (2) net foreign exchange loss/(gain), (3) one-off expenses in relation to acquisitions, and (4) changes in fair value of financial assets at FVTPL. Adjusted net profit attributable to owners of the Company is not an alternative to (i) profit before tax, profit for the year or profit for the year attributable to owners of the Company (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity. We believe that this non- IFRS measure is useful for understanding and assessing underlying business performance and operating trends, and that the owners of the company and we may benefit from referring to this non-IFRS measure in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and/or non-operating items that we do not consider indicative of the performance of our business. However, the presentation of this non-IFRS measure is not intended to, and should not, be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS measure on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results or a similarly titled financial measure reported or forecasted by other companies. ●Tigermed 2#301 Interim Results Overview ● Tigermed#41H2023 Key Financials Revenue (RMB mm) +3.2% Gross Profit and Margin 39.5% (RMB mm) 39.5% Adjusted Net Profit Attributable to the Owners of the Company and Margin (1) (RMB mm) 24.4% 24.1% +3.4% +2.2% 3,594.2 3,710.9 1,418.3 1,466.3 876.5 895.6 1,422.1 1,607.5 617.6 640.8 2,172.1 2,103.4 800.7 825.5 1H2022 1H2023 Clinical trial solutions Clinical-related and laboratory services 1H2022 1H2023 Clinical trial solutions Clinical-related and laboratory services 1H2022 1H2023 ●Tigermed (1) Non-IFRS measure. Adjusted for (i) share-based compensation expense, (ii) net foreign exchange loss/(gain), (iii) amortization of intangible assets arising from acquisitions, and (iv) changes in fair value of financial assets at FVTPL 4#5Revenue Breakdown by China and Overseas Markets China Revenue (RMB mm) +24.2% Overseas Revenue (RMB mm) -15.2% Revenue Breakdown by Region 47% 1H2022 53% 2,087.4 1,913.4 ■China Overseas 1,680.8 1,623.5 1H2022 1 H2023 1H2022 1H2023 ● Tigermed 44% 1H2023 56% ■China Overseas 5#6Cost of Services ●Tigermed Cost of Services Breakdown by Nature and as % of Revenue (RMB mm) 60.5% 60.5% 2,175.9 +3.2% 2,244.6 5.2% 6.7% 28.9% 26.4% 1H2022 Direct labor costs Direct project-related costs 23.6% 30.2% 1 H2023 Overhead costs 6#7Operating Expenses Selling and Marketing Expenses and as % of Revenue 2.2% (RMB mm) Administrative Expenses and as % of Revenue 2.4% 8.9% (RMB mm) R&D Expenses and as % of Revenue 9.4% 3.1% (RMB mm) Share-based Compensation and as % of Revenue 3.5% 0.7% (RMB mm) 1.5% +11.3% +9.0% +15.9% 128.1 89.0 80.0 350.2 110.5 321.4 +116.4% 25.6 55.4 1H2022 1H2023 1H2022 1H2023 1H2022 1H2023 1H2022 1 H2023 ● Tigermed 7#802 Business Updates Clinical Trial Solutions ● Tigermed#9Clinical Trial Solutions ("CTS") ●Tigermed Segment Revenue (RMB mm) 2,172.1 1H2022 -3.2% 2,103.4 Segment Gross Profit and Margin (RMB mm) 36.9% +3.1% 39.2% 800.7 825.5 1H2023 1H2022 1H2023 6#10CTS Key Business Updates Number of Ongoing Drug Clinical Research Projects by Phase(1) Number of Ongoing Drug Clinical Research Projects by Region (1) 800 772 800 772 74 62 680 680 700 700 35 607 67 607 62 600 34 600 207 52 185 58 37 188 500 160 500 149 149 400 146 400 134 300 117 300 503 200 430 200 400 332 285 252 100 100 0 06/30/2022 12/31/2022 06/30/2023 ■Phase I (including PK studies) Phase II Phase III Phase IV Others (1) As of year/period end ● Tigermed (2) Others primarily consist of investigator-initiated studies and real world studies 0 (2) 06/30/2022 12/31/2022 06/30/2023 ■PRC (single region) Overseas (single region) MRCTs 10 10#11CTS Key Business Updates (Cont'd) Overseas Clinical Operation Business Updates Number of Ongoing Overseas Drug Clinical Research(1) Tigermed 269 250 62 207 62 58 207 188 149 06/30/2022 12/31/2022 ■Overseas (single region) ■MRCTS (1) As of year/period end (2) Source: Frost & Sullivan 06/30/2023 Total employees reached 9,455, of which 1,525 employees based overseas Opened International Headquarters in Hong Kong for establishing a business and functional management hub for our global development Acquired Marti Farm in Croatia, further strengthening our ability to provide high quality clinical services in Europe to our global customers Global team comprising 1,150+ clinical research associates, 2,800+ clinical research coordinators, 800+ for data management and statistical analysis and 1,600+ for laboratory services as of June 30, 2023 The only Chinese company that was ranked as top 10 clinical CROS globally in 2022 by revenue, with a market share of 1.5% (2) Added 8 newly signed MRCT projects in 1H2023, with a cumulative experience of handling over 120 MRCT projects 11#12CTS Key Business Updates (Cont'd) Overseas Clinical Operation Business Updates (Cont'd) As of June 30, 2023, we have established collaborations with over 100 clinical sites in the United States, covering 33 states. The size of our US clinical operation team has more than doubled from June 30, 2022, reaching 110 employees As of June 30, 2023, we have over 40 ongoing clinical trials in the United States, including single region clinical trials and MRCTs. The scope of therapeutic areas covered in our ongoing trials in the United States continues to expand. Starting from oncology, we have extended to vaccines, ophthalmology, dermatology, rare diseases, neurology, and cardiovascular etc. Completed the acquisition of Marti Farm and integrated Marti Farm's clinical operation and pharmacovigilance teams with our existing business, which further strengthened our ability to provide high quality clinical services in Europe to our global customers Established a local business development team in Europe and have integrated, expanded, and improved the capacity and capability of our clinical operation and supporting teams in Europe. Multiple services including clinical operation, clinical trial design, project management, medical monitoring, post-market studies, pharmacovigilance and quality assurance have been integrated under a single team force to response to customers' demands as an integrated service platform As of June 30, 2023, we have 35 ongoing clinical trial projects (including medical device clinical trials and MRCTs) in the EMEA (Europe, Middle East, Africa) region and our employees and operational entities cover 16 countries in the EMEA region As of June 30, 2023, we also have 31 ongoing clinical trial projects in South East Asia and Latin America regions, including 23 MRCTs, covering multiple therapeutic areas including oncology, vaccines, cardiovascular, endocrine, and infectious disease etc. ●Tigermed 12#13CTS Key Business Updates (Cont'd) Global R&D Services and Operations Network 000000001 North America • • Team Size: 800+ Local Clinical Monitoring and PM Team in the United States Preclinical laboratories and facilities located in 8 cities across North America Collaborating with over 100 clinical sites in the United States Clinical monitoring / project management / DMSA / site management / regulatory, etc. M 00000 00000 ●Tigermed EMEA • Team Size: 80+ China CRA and PM covering key European countries Full clinical operational capabilities and functional support Collaborated with clinical sites in multiple African countries Clinical monitoring / project management/ pharmacovigilance / regulatory/clinical operations, etc. 000 . Team Size: 7,900+ The Largest Clinical CRO in China Collaborating with over 1300 clinical sites Clinical operation services with full industry chain capabilities Global functional support and business hub Full preclinical research and development capabilities with GLP laboratories Clinical monitoring / regulatory / site management / project management/imaging / DMSA / medical devices / medical translation / medical writing / patient recruitment / pharmacovigilance, etc. • . . South America Team Size: 12 Local clinical operations and project management teams based in multiple South American countries Conducted multiple large vaccine clinical studies Clinical Monitoring / Project Management / Clinical Operations 0000 00 000 0000000 00000 Asia Pacific • • Team Size: 500+ Local offices in 10+ countries including Japan, South Korea, Australia, Malaysia, Singapore, India, and other SEA countries Local Clinical Operations and Project Management Team Conducted multiple large-scale vaccine clinical studies Clinical Monitoring / Project Management / Clinical Operations / DMSA 13#14CTS Key Business Updates (Cont'd) Regulatory Affairs ("RA") As of June 30, 2023, we have a total of 940 accumulated RA project experience In the first half of 2023, we also added 18 new U.S. Food and Drug Administration (“FDA IND”) projects, of which 9 of them have successfully filed and were cleared for clinical trial In the first half of 2023, we assisted 7 products to be registered and approved in China, as well as assisted with 16 Investigational New Drug ("IND")/ MRCT clinical trial filings in multiple countries The number of customers increase to 700 as of June 30, 2023, from 649 as of December 31, 2022 Medical Device & IVD As of June 30, 2023, our medical device team has served more than 1,700 global clients, accumulated experience over more than 5,700 medical device and IVD project registration projects, and more than 700 medical device and IVD clinical trials We offer an integrated service that covers the full lifecycle of medical device R&D, providing services that cover product development strategy, pre-clinical trial, clinical trial, registration, and post-market Rewarded as "Best Medical Device Overseas Enabling Service Provider of 2023"(1) ● Tigermed (1) Awarded by China-Go-Global Medical Device Conference 14#15CTS Key Business Updates (Cont'd) Pharmacovigilance ("PV") We completed the integration of Marti Farm's pharmacovigilance teams with our existing pharmacovigilance team in China, providing safety monitoring solutions to both pre-NDA and post-market projects for drugs, medical devices, vaccines and aesthetics etc. in both Europe and China In the first half of 2023, we further established the pharmacovigilance capabilities for cosmetics and aesthetics medicines In the first half of 2023, our pharmacovigilance services added 75 newly signed projects and 59 new customers Medical Translation In the first half of 2023, we added 52 new customers, including 26 pharmaceutical companies and 26 medical device companies cooperated with local Japanese language service and translation companies to expand the Japanese market We improved the efficiency of our medical translation services by developing in-house digital platforms, bundling translation systems and services into the clinical operation system. We also continued to tailor our translation platform for academia and educational usage during the Reporting Period. We improved our industry-leading architecture of translation technology, which is a full-process production and delivery platform composed of custom- developed application-layer tools based on artificial intelligence algorithms and big data model engines According to CSA Research, our medical translation business ranked 51st globally (5th in Chinese Mainland and 14th in Asia Pacific) in the 2022 CSA Research Largest Language Service Providers Ranking (1) ● Tigermed (1) Including language services of all sectors and industries. Source: https://analytics.csa-research.com/gms-ranking/top-100-lsps 15 15#16CTS Key Business Updates (Cont'd) Real World Studies We successfully reached multiple real-world study collaborations with an multi-national pharmaceutical company. Research collaborations with universities and hospitals on real world studies has been further strengthened, including a 14th Five-Year Plan national level project cooperation with the Chinese University of Hong Kong and a multi-center investigator-initiated trial with the Chongqing Medical University We have also introduced DCT technology and mode into our real-world study projects, using artificial intelligent follow-up tools and self- developed e-Clinical Trial Patient Management system (eCPM), effectively improving subject compliance and the efficiency and accuracy of self-reported data, and could potentially reduce the project cost by more than 40% Vaccine Clinical Services Provides the one-stop phase I-IV vaccine clinical research solution, service offerings including vaccine clinical trial design, DMSA, clinical trial operation, electronic data capture and site management etc. We successfully helped the first Chinese vaccine to obtain the clearance to conduct the phase I clinical trial in the United States In the first half of 2023, we also supported multiple phase III protective efficacy research for innovative vaccines in Provincial CDC and hospitals in China including chickenpox, RSV, S. aureus and therapeutic BCG etc. As of June 30, 2023, our vaccine clinical service team has conducted 14 overseas COVID-19 vaccine projects, 8 of those are phase III pivotal clinical studies, covering 17 countries across Asia-Pacific, Latin America, Europe, and Africa, and having enrolled a total of more than 150,000 subjects ● Tigermed 16 16#1703 Business Updates Clinical-related and Lab Services ● Tigermed#18Clinical-related and Lab Services ("CRLS") ● Tigermed Segment Revenue (RMB mm) 1,422.1 +13.0% 1,607.5 Gross Profit and Margin 43.4% (RMB mm) 39.9% +3.8% 617.6 640.8 1H2022 1 H2023 1 H2022 1H2023 18#19CRLS Key Business Updates Project Status for Key CRLS Services Data Management and Statistical Analysis Site Management Laboratory Services 306 Conducted by team based overseas 553 Completed Conducted by team Completed based in China 1,776 Completed 2,872 1,994 5,002 4,667 157 105 203 228 83 122 2020 2021 2022 06/30/2023 2020 2021 2022 06/30/2023 2020 2021 2022 Ongoing Ongoing 06/30/2023 Ongoing ●Tigermed 19#20CRLS Key Business Updates (Cont'd) Data Management & Statistical Analysis ("DMSA") . As of June 30, 2023, our DMSA team had over 800 professionals based in China, South Korea, the United States and India As of June 30, 2023, we had 296 DMSA customers and 859 ongoing DMSA projects The project service cooperation mode can be customized according to customer needs Released 5 products of the DIS automation tools in 1H2023, including the Tigermed CRF template, TFL Shell automation tool, SDTM aCRF automation tool, CDISC SDTM Macros and Define Generator tool Completed applications for 14 high-tech software certifications in 1H2023 Laboratory Services The new 8,000 square meters clinical trial manufacturing facility in Suzhou was officially put into operation, further improving our capacity in Good Manufacturing Practice ("GMP”) clinical trial manufacturing and meeting the more diversified customer needs The Wuhan R&D center of ACME Biopharma, a subsidiary of Frontage, was officially opened on May 15, 2023. With a total space of 18,000 square meters, the first phase of the R&D center has a capacity of 50 chemical pharmacology laboratories, 4 formulation development laboratories, and a testing and analysis center, providing one-stop R&D from target screening to pre-clinical pharmacology research On June 6, 2023, our Suzhou Safety Assessment Center obtained the GLP (Good Laboratory Practice) certification issued by the NMPA, which demonstrated that Frontage Suzhou Safety Assessment Center has met the requirements of GLP regulations in terms of organizational structure and personnel training, equipment and computerized systems, laboratory materials, standard operating procedures and test operation ●Tigermed 20 20#21CRLS Key Business Updates (Cont'd) Decentralized Clinical Trials ("DCTS" In the first half of 2023, Tigermed Decentralized Clinical Trials ("DCTS") Solutions were fully or partially applied in multiple projects covering therapeutic areas such as oncology, Alzheimer's disease, migraine, diabetes and COVID-19 etc. We created functions such as remote follow-up, remote monitoring, remote informing, electronic patient report, wearable devices etc. We compiled The Tigermed DCT Global Regulatory Handbook, to provide a regulatory reference and guide for DCT applications in global clinical research, which will be released soon • We are developing DCT eConsent, E2E, CTCM, and other systems. After completion and putting into use, these systems will make the DCT service platform more comprehensive and flexible to provide customers with decentralized clinical trial solutions. We participated in multiple regulatory and industry projects and seminars on the construction of decentralized clinical trial regulations L DHT/Digital Medicine eConsent ¿Ð eCOA/ePRO /eDiary /IRT/DTP -. E E2E Tigermed DCT Platform EDC Al Follow up 眉 eCPM eTMF CTMS 000 RBQM ePAY B CTRM/CTC M • Tigermed 21 224#22CRLS Key Business Updates (Cont'd) Site Management ("SMO") . As of June 30, 2023, we had 1,776 ongoing site management projects and completed 105 site management projects As of June 30, 2023, we had over 2,800 Clinical Research Coordinators ("CRC"s), covering more than 140 cities across China Provided SMO services to 11 Class I innovative drug approvals in China in 1H2023 Clinical Trial Sites of Excellence ("E-Site") As of June 30, 2023, our Excellence for Clinical Trial Sites ("E-Site") Program had 204 core collaborative sites and 61 green channel sites across China, completed the signing of 39 strategic cooperation sites and the establishment of 6 co-sites, forming a diversified and win-win strategic cooperation model As of June 30, 2023, 17 full-time on-site staff were deployed to strategic collaboration sites in Beijing, Shanghai, Jiangsu, Zhejiang, Hunan, Hubei, Shandong, Fujian, Chongqing, and Anhui, assisting the sites in efficiently managing and operating clinical projects, deepening the collaboration with the sites, and jointly accelerating drug research and development efficiency We started to provide new services including GCP qualification application and filing support, project bidding and import process support and project initiation process optimization to our E-Site partners. ● Tigermed 22 22#2304 Other Updates ● Tigermed#24Updates of Investment Activities ● Tigermed Realized Investment Gain and Fair Value Gain(1) (RMB mm) 50.1 413.3 1 H2022 34.9 529.8 Portfolio included 158 companies in the healthcare industry and 59 investment funds as of June 30, 2023 RMB 10,633.3 mm balance as of June 30, 2023 Invested RMB 239.3 mm in unlisted equities; and RMB 22.9 mm in investment funds in 1H2023 Received RMB 383.4 mm cash from investment exits in 1H2023 In 1H2023, we realized a gain of RMB 152.3 million from exiting our portfolio companies and funds, as measured by the exit amount against our initial investment cost 1H2023 Realized investment gain Fair value gain (1) Realized Investment gain indicates gain on disposal of or dividends from financial assets at fair value through profit or loss ("FVTPL") and gain on disposal of associates or subsidiaries for investment purposes; fair value gain indicates change in fair value of financial assets at FVTPL 24 24#25Employee Base Total employees increased to 9,455 as of June 30, 2023 from 9,233 as of December 31, 2022 Employees Mix by Function(1) Employees Mix by Geography (1) Marketing and business Management and administration 550 Overseas and Hong Kong China, Macau China, Taiwan China 1,525 development 429 6% 4% 16% Tigermed (1) As of June 30, 2023 90% Project operations 8,476 84% Chinese Mainland 7,930 25 25#26Opening of International Headquarters in Hong Kong Tigermed Grand Opening of Tigermed International Headquarters in Hong Kong 祝賀泰格醫藥國際組在香港落成 Hong Ko Tigermed germed Tigermed Tigermed Our International Headquarters was officially opened in Hong Kong on August 16, 2023 This is another milestone in the Group's international operation, following the establishment of a subsidiary in Hong Kong in September 2011 and our listing on the Hong Kong Stock Exchange in August 2020, building a new platform for developing future overseas businesses The International Headquarters will enable Tigermed to coordinate and manage global projects more efficiently, drive business expansion, and empower customers on a global scale. Besides, it will bring new energy to the company's service platform, global talent, supporting functions, corporate culture, and beyond By further extending our clinical service platform to Hong Kong, we aim to provide high- quality clinical CRO services to innovative pharmaceutical and medical device companies in Hong Kong and Asia Pacific region more conveniently and efficiently We hope to obtain more global innovative clinical research projects through collaboration with leading researchers, investigators and institutions in Hong Kong and Asia Pacific in future We also aim to attract more clinical professionals with global expertise and mindset through the new office in Hong Kong Tod ening Ceremony of termed international adquarters ng Kong at 16 2023 Hong l Platform one Tige-med ●Tigermed Leading CRO with bal Reach and ven Expertise Tigermed Tigermec Obamed bal Platform One Tigermed 26 26#2705 Appendix ● Tigermed#28Consolidated Statement of Profit or Loss (RMB 000s) Revenue Cost of services Gross profit Other income Other gains and losses, net Impairment losses Selling and marketing expenses Administrative expenses Research and development expenses Share of losses of associates Finance costs Profit before tax Income tax expense Profit for the year Profit attributable to owners of the Company Adjusted for: Share-based compensation expense Net foreign Exchange loss/(gain) Year ended June 30, 2022 3,594,209 (2,175,881) 2023 3,710,850 (2,244,568) 1,418,328 1,466,282 128,757 147,146 468,609 571,836 (28,411) (29,777) (80,040) (88,998) (321,379) (350,171) (110,520) (128,082) 35,556 63,724 (31,035) (52,815) 1,479,865 1,599,145 (162,239) (191,055) 1,317,626 1,408,090 1,192,004 1,388,337 16,673 (1,829) 48,476 (17,659) Amortization of intangible assets arising from acquisitions 17,225 Change in fair value of financial assets at FVTPL (347,542) Adjusted net profit attributable to owners of the Company(1) 876,531 5,472 (529,013) 895,613 ●Tigermed (1) Non-IFRS measure 28#29Consolidated Statement of Financial Position (RMB 000s) NON-CURRENT ASSETS Property, plant and equipment Intangible assets Goodwill Right-of-use assets Interests in associates Other financial assets at amortized cost Deferred tax assets As of December 31, 2022 As of June 30, 2023 16,341,353 976,679 276,147 2,485,018 622,354 1,799,825 17,692,426 1,049,760 270,413 2,549,178 584,058 2,413,561 27,607 39,087 121,353 Financial assets at fair value through profit or loss ("FVTPL") 9,963,853 141,532 10,609,474 Financial assets at fair value through other comprehensive income ("FVTOCI") 3,864 3,844 Restricted bank deposits 2,089 2,168 Other non-current assets 62,564 29,351 CURRENT ASSETS Inventories 11,105,157 11,974,249 22,204 26,532 Trade, bills and other receivables and prepayments 1,186,273 1,398,473 Contract assets Financial asset through P&L - Current Prepaid income tax Restricted bank deposits Time deposit with original maturity over three months Cash and cash equivalents Assets classified as held for sales 1,997,311 2,364,142 24,946 20,000 15,136 29,358 19,115 6,884 54,194 32,688 7,782,741 3,237 8,096,172 ●Tigermed 29 29#30Consolidated Statement of Financial Position (Cont'd) (RMB 000s) CURRENT LIABILITIES Trade and other payables Contract liabilities Bank borrowings Income tax payables Lease liabilities/obligations under finance leases NON-CURRENT LIABILITIES Non-current Bank borrowing Lease liabilities/obligations under finance leases - non current Deferred government grant Pension obligations Other long-term liabilities Deferred tax liabilities NET ASSETS TOTAL EQUITY Share capital Treasury shares Retained earnings Equity attributable to owners of the Company Non-controlling interests ●Tigermed As of December 31, 2022 As of June 30, 2023 3,729,569 717,950 939,765 1,868,215 85,875 4,633,250 1,149,121 876,381 2,390,088 98,295 117,764 119,365 1,035.913 1,075,576 244,641 288,571 488,976 14,786 425 72,692 453,103 15,115 461 86,937 214,393 231,389 22,681,028 22,681,028 23,957,849 23,957,849 872,419 (869,340) 872,419 (869,340) 19,625,366 20,635,416 19,628,445 20,638,495 3,052,583 3,319,354 30 30#31Tigermed 300347.SZ/3347.HK Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com